Sponsors
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Focus Area: Drug Discovery
The changing landscape of drug development
The challenge for IT is to partner with the business to enable change, rather than impede it.
Head to head: The future of web-based reporting
Dr. Steven Gold, Founder and CEO of GraphLogic, and Dr. Simon Wood, Executive Director of Marketing and Education for STARLIMS, discuss superior alternatives to traditional software.
A new grammar for drug discovery
NGP’s Julia Puppe spoke with Mark Fishman, Head of Biomedical Research at Novartis, about the strategy behind his company’s new approach to clinical research.
Head to head: with big pharma
Amgen, a small West Coast based biotech who was hardly on the map ten years ago, last year produced four of the top 20 drugs in the US market by sales.
Partnering up
Mark Strobeck explains the importance of balance when engaging in partnerships that accelerate the drug discovery process.
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.